TJ013

TJ013 is a small molecule drug candidate developed by Tuojie Biotech (拓界生物医药) that targets Hypoxia-Inducible Factor (HIF). HIF is a transcription factor that plays a pivotal role in the cellular response to hypoxia, regulating genes involved in angiogenesis, cell survival, and metabolism. In the context of oncology, HIF is often overexpressed in the hypoxic environment of solid tumors, contributing to tumor progression and resistance to therapy. TJ013 is designed to modulate this pathway, potentially serving as an antineoplastic agent. It is currently in the early stages of development as part of Tuojie Biotech's small molecule pipeline, which focuses on innovative therapies for cancer and metabolic diseases.